Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

This study is tracking outcomes for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are treated using blue light cystoscopy during their bladder tumor removal surgery (TURBT). Blue light technology makes cancer cells glow, helping surgeons more accurately detect and remove tumors. Researchers want to see if this approach improves long-term outcomes. **You may be eligible if...** - You are 18 or older - You are having TURBT surgery for a bladder tumor seen on imaging or scope - You start an intravesical (directly into the bladder) therapy within four weeks of surgery - Your upper urinary tract (kidneys and ureters) will be evaluated as part of standard care throughout the study **You may NOT be eligible if...** - Your tumor has less than 50% urothelial (bladder lining) cell type - You have or have had cancer in the upper urinary tract, or muscle-invasive bladder cancer - You have previously had pelvic radiation - You currently have an active urinary tract infection - You are unlikely to follow the study protocol Talk to your doctor to see if this trial is right for you.